Achieving Complete Remission Of Mcl

Achieving Complete Remission of MCL

Targeted Oncology

Every patient in small cancer study achieves complete remission

Phase II trial of acalabrutinib, lenalidomide and rituximab in patients with MCL

VJHemOnc – Video Journal of Hematology & HemOnc

Update on Phase I/II study of glofitamab monotherapy in R/R MCL

VJHemOnc – Video Journal of Hematology & HemOnc

The Next Phase of Targeted Therapy in MCL and DLBCL

PeerView Oncology

Advice for Treating Patients With MCL

Targeted Oncology

Acalabrutinib and rituximab as first-line therapy for older patients with MCL

VJHemOnc – Video Journal of Hematology & HemOnc

Therapy for Relapsed or Refractory MCL

Targeted Oncology

Treatment approaches for older patients with MCL

VJHemOnc – Video Journal of Hematology & HemOnc

Update on Relapsed/Refractory Mantle Cell Lymphoma | LRF Webinars

Lymphoma Research Foundation

The changing definition of complete remission in multiple myeloma

VJHemOnc – Video Journal of Hematology & HemOnc

Prognostic markers in MCL and the value of CAR-T therapy in treating high-risk disease

VJHemOnc – Video Journal of Hematology & HemOnc

The success of ibrutinib in treating mantle cell lymphoma (MCL)

VJHemOnc – Video Journal of Hematology & HemOnc

BTK inhibitors for R/R MCL: current uses and insights from the ViPOR study

VJHemOnc – Video Journal of Hematology & HemOnc

Autologous transplantation followed by maintenance vs maintenance alone in patients with MCL

VJHemOnc – Video Journal of Hematology & HemOnc

There Are Multiple Ways to Treat R/R CLL or R/R MCL: What Would the Experts Do?

Taking the Leap With Innovative Strategies in MCL

PeerView Oncology

How to Treat Patients With Relapsed/Refractory Mantle Cell Lymphoma

Targeted Oncology

How to manage relapsed/refractory MCL - new agents and unmet needs

VJHemOnc – Video Journal of Hematology & HemOnc

Mantle Cell Lymphoma (Case Studies)